Immunovant (IMVT) Interest Expenses (2019 - 2026)
Immunovant's (IMVT) quarterly Interest Expenses came in at $312.0 million in Q1 2026, up 42.6% YoY from $218.8 million in Q1 2025, and up 166.2% on a QoQ basis from $117.2 million in Q4 2025.
Immunovant (IMVT) Interest Expenses (2019 - 2026) Analysis & Trends
Immunovant (IMVT) has 8 years of Interest Expenses data on file, last reported at $312.0 million in Q1 2026.
- Quarterly Interest Expenses rose 42.6% year-over-year to $312.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $312.0 million (up 42.6% YoY) and the FY2026 annual result came in at $312.0 million, up 42.6% from the prior year.
- Interest Expenses grew to $312.0 million in Q1 2026, from $117.2 million in the prior quarter.
- In the past five years, Interest Expenses ranged from a high of $429.4 million in Q4 2023 to a low of $13000.0 in Q2 2022.
- A 5-year average of $151.1 million and a median of $117.2 million in 2025 frame the typical range for Interest Expenses.
- Annual changes were most pronounced in 2022 — Interest Expenses slumped 99.84% — and 2023, when it jumped 1032776.92%.
- Tracing IMVT's Interest Expenses over 5 years: stood at $114.6 million in 2022, then surged by 274.81% to $429.4 million in 2023, then tumbled by 58.34% to $178.9 million in 2024, then tumbled by 34.49% to $117.2 million in 2025, then jumped by 166.2% to $312.0 million in 2026.
- The last three Interest Expenses figures came in at $312.0 million (Q1 2026), $117.2 million (Q4 2025), and $48.1 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 439.40 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 52.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.70 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 39.74 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 335,572.77 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 218.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 82.05 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 20.27 Mn |
| 10 | Immunovant | 8.63 Bn | 7.83 Bn | - | 184.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 184.60 Mn |
| Jun 30, 2026 | 184.60 Mn |
| Mar 31, 2026 | 312.00 Mn |
| Mar 31, 2026 | 312.00 Mn |
| Dec 31, 2025 | 117.20 Mn |
| Dec 31, 2025 | 117.20 Mn |
| Sep 30, 2025 | 48.09 Mn |
| Sep 30, 2025 | 48.09 Mn |
| Jun 30, 2025 | 73.81 Mn |
| Jun 30, 2025 | 73.81 Mn |
| Mar 31, 2025 | 218.80 Mn |
| Mar 31, 2025 | 218.80 Mn |
| Dec 31, 2024 | 178.90 Mn |
| Dec 31, 2024 | 178.90 Mn |
| Sep 30, 2024 | 235.08 Mn |
| Sep 30, 2024 | 235.08 Mn |
| Jun 30, 2024 | 216.77 Mn |
| Jun 30, 2024 | 216.77 Mn |
| Mar 31, 2024 | 3.36 Mn |
| Mar 31, 2024 | 3.36 Mn |